Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis

3Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Allergen immunotherapy (AIT) is effective in patient with local allergic rhinitis (LAR). However, AIT may not always achieve the optimal treatment effect. Objective: To present short study with clinical cases of LAR combined therapy with sublingual immunotherapy (SLIT) and omalizumab in patients with house dust mite (HDM) allergy and compared it to therapy with omalizumab alone. Methods: Patients with severe LAR and hypersensitivity to HDMs were included. SLIT for HDMs was launched in a perennial protocol using SQ-HDM SLIT tablets with omalizumab. The total rhinitis symptom score (TRSS), total medication score (TMS) and combined total score (CTS) were assessed after one year. Results: After 12 months, significant improvements in all analyzed parameters in the patients on SLIT+ omalizumab therapy were observed: a reduction in the TRSS from 1.21 ± 0.33 to 0.6 ± 0.28 (p

Cite

CITATION STYLE

APA

Bozek, A., Kozłowska, R., Misiołek, M., Ścierski, W., & Gawlik, R. (2022). Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis. Human Vaccines and Immunotherapeutics, 18(6). https://doi.org/10.1080/21645515.2022.2097818

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free